论文部分内容阅读
多数因左心室功能不全而致的慢性心衰患者发生猝死,其原因并非心衰加重而是室性心律失常。然而很多抗心律失常药物的心肌抑制作用抵消了抗心律失常作用,因而并不能改善心衰患者的预后。乙胺碘呋酮是第Ⅲ类抗心律失常药物,有强力扩张冠状动脉及外周动脉作用,大剂量静脉注射有短时心肌抑制作用,但长程口服治疗对心肌抑制极轻。本文用乙胺碘呋酮及安慰剂双盲、交叉对照试验,研究其对心衰患者症状、运动耐量、左室功能及抗心律失常的治疗效果。 22例(男19例)心衰半年以上的患者,年龄平均
Most patients with chronic heart failure due to left ventricular dysfunction, sudden death, the reason is not due to heart failure but ventricular arrhythmias. However, many antiarrhythmic drugs counteract the anti-arrhythmic effect of myocardial inhibition and thus do not improve the prognosis of patients with heart failure. Amiodarone is a Class III anti-arrhythmic drug with a powerful dilatation of the coronary arteries and peripheral arteries. High-dose intravenous infusion has short-term myocardial inhibition, but long-term oral therapy has minimal myocardial inhibition. In this study, amiodarone and placebo double-blind, cross-over control study of patients with heart failure symptoms, exercise tolerance, left ventricular function and anti-arrhythmia treatment. 22 patients (19 males) with heart failure more than six months, average age